Suraj Muley

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

Ivo N. van Schaik, Vera Bril, Nan van Geloven et al. · The Lancet Neurology · 2017 · 258 citations · Full text

Subcutaneous Immunoglobulin, Autoimmune Disease, Chronic Inflammatory +12

The Quantitative Evaluation of Functional Neuroimaging Experiments: The NPAIRS Data Analysis Framework

Stephen C. Strother, Lars Kai Hansen, Ulrik Kjems et al. · NeuroImage · 2002 · 251 citations

Neuroimaging Biomarkers, Functional Neuroimaging Experiments, Neuroimaging Modality +13

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial

Gil I. Wolfe, Henry J. Kaminski, Inmaculada Aban et al. · The Lancet Neurology · 2019 · 216 citations · Full text

The Evaluation of Preprocessing Choices in Single-Subject BOLD fMRI Using NPAIRS Performance Metrics

Stephen M. LaConte, Jon Anderson, Suraj Muley et al. · NeuroImage · 2002 · 123 citations

Neuroimaging Biomarkers, Cognitive Science, Neuroimaging Modality +10